Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avutometinib +/- Defactinib in KRAS/BRAF mutant NSCLC (RAMP 202)
NCT04620330Phase 2Completed
- Sponsor
- Verastem Oncology
- Start
- Dec 2020
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of avutometinib in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Verastem Oncology. Primary endpoints: Optimal Regimen Selection (Mono vs Combo in KRAS G12V) at 24 weeks and Objective Response Rate at 24 weeks. Started Dec 2020; status: completed.
02
Drugs
avutometinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04620330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04620330.